IL2 and cancer: However, IL-2 is only effective against cancer at high doses, due to its weaker interaction with dimeric IL-2R-expressing NK and effector T cells compared with trimeric IL-2R-expressing Treg cells, as well as the cytokine’s extremely short half-life.